Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Frequently asked questions
What sector does Syndax Pharmaceuticals Inc (1T3) operate in?
Syndax Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Syndax Pharmaceuticals Inc (1T3) current stock price?
As of the latest data, Syndax Pharmaceuticals Inc stock price is €11.74, with a previous close of €11.87. Syndax Pharmaceuticals Inc lost -€0.13 in the last trading session, representing a -1.1% loss.
What is Syndax Pharmaceuticals Inc (1T3) current market capitalization?
Syndax Pharmaceuticals Inc market cap is approximately 1.05 billion.
What is Syndax Pharmaceuticals Inc (1T3) Earnings Per Share (EPS)?
The trailing EPS is -€2.16.
What is Syndax Pharmaceuticals Inc (1T3) EBITDA?
Syndax Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -32.12 million.
Does Syndax Pharmaceuticals Inc (1T3) pay dividends?
No. Syndax Pharmaceuticals Inc does not pay a dividend.
When is Syndax Pharmaceuticals Inc (1T3) next earnings report?
Syndax Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is Syndax Pharmaceuticals Inc (1T3) beta (volatility) score?
Syndax Pharmaceuticals Inc has a beta of 0.424, indicating lower volatility than the overall market.
